Price Alert

Halozyme Therapeutics Inc... (HALO)

NASDAQ: HALO · Real-Time Price · USD

67.28

1.74 (2.65%)

At close: Aug 15, 2025, 3:59 PM

67.30

0.03%

After-hours: Aug 15, 2025, 06:17 PM EDT

2.65% (1D)

Bid	66.15
Market Cap	7.87B
Revenue (ttm)	1.18B
Net Income (ttm)	557.28M
EPS (ttm)	4.37
PE Ratio (ttm)	15.4
Forward PE	8.22
Analyst	Buy

Ask	67.79
Volume	1,193,568
Avg. Volume (20D)	2,376,241.5
Open	66.11
Previous Close	65.54
Day's Range	65.77 - 67.39
52-Week Range	42.01 - 70.51
Beta	1.17

About HALO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol HALO

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for HALO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Halozyme Therapeutics has released their quartely earnings on Aug 5, 2025:

Revenue of $325.72M exceeds estimates by $39.72M, with 40.79% YoY growth.

EPS of 1.54 exceeds estimates by 0.34, with 69.23% YoY growth.

Next Earnings Release

Halozyme Therapeutics Inc. is scheduled to release its earnings on Oct 30, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+2.48%

Halozyme shares are trading higher after the compa... Unlock content with Pro Subscription

1 week ago

+1.37%

Halozyme shares are trading higher after the company raised FY25 guidance.

News

5 days ago · zacks.com

Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

1 week ago · zacks.com

After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is Bright

Halozyme Therapeutics, Inc. (HALO) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, HALO's 50-day simple moving average crosse...

1 week ago · zacks.com

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

1 week ago · zacks.com

HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View

Halozyme jumps 5.3% on second-quarter earnings and revenue beat, fueled by strong royalty growth, and a raised 2025 outlook.

1 week ago · 247wallst.com

Analysts Just Upgraded these Five Stocks

Bank of America reiterated its buy rating on Palantir with a price target of $180.

1 week ago · seekingalpha.com

Halozyme Therapeutics, Inc. (HALO) Q2 2025 Earnings Call Transcript

Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Helen I. Torley - President, CEO & Director Nicole LaBrosse - Senior VP & CFO...

1 week ago · fool.com

Halozyme (HALO) Q2 EPS Jumps 69%

1 week ago · zacks.com

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with...

1 week ago · zacks.com

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.54 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $0.91 per share a year ago.

2 weeks ago · zacks.com

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Load More News